Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)
0.2407
-0.0194 (-7.46%)
NASDAQ · Last Trade: Apr 6th, 6:22 AM EDT
Detailed Quote
Previous Close
0.2601
Open
0.2300
Bid
0.2190
Ask
0.2200
Day's Range
0.2300 - 0.2530
52 Week Range
0.2102 - 1.570
Volume
1,858,613
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
10,205,797
Chart
About Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)
Quoin Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for rare and specialty diseases. The company specializes in creating and advancing treatments that address unmet medical needs, particularly in the areas of dermatology and other niche therapeutic segments. Through its research and development efforts, Quoin aims to provide effective solutions that improve patient outcomes and enhance the quality of life for those affected by challenging health conditions. The company's approach combines scientific expertise with a commitment to bringing new medications to market, fostering collaborations within the healthcare community to drive forward its mission. Read More
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant achievements in 2024 and 2025, through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment.
